NCT05827055 - Proglumide and Chemotherapy for Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

Gemcitabine

1000mg/m2 IV given days 1, 8, and 15 every 28 days (1 cycle)

DRUG

Nab paclitaxel

125 mg/m2 given days 1, 8, and 15 every 28 days (1 cycle)

DRUG

Proglumide

Daily dose of 1200 mg orally given as 400 mg orally (PO), three times a day (TID) in vegan capsules

DRUG

Placebo

Placebo given in vegan. capsules orally three times a day

Trial Locations (1)

Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C.

All Listed Sponsors

lead

Georgetown University

OTHER